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Abstract Rituximab (RTX), an anti-CD20 monoclonal
antibody, has been proposed for use in the therapy of
systemic lupus erythematosus (SLE). We present the initial
long-term experience of the safety and efficacy of rituximab
for treatment of SLE in children. Eighteen patients (mean
age 14±3 years) with severe SLE were treated with
rituximab after demonstrating resistance or toxicity to
conventional regimens. There was a predominance of
female (16/18) and ethnic African (13/18) patients. All
had lupus nephritis [World Health Organization (WHO)
classes 3–5] and systemic manifestations of vasculitis.
Clinical disease activity of the SLE was scored with the
SLE-disease activity index 2K (SLEDAI-2K). Patients were
followed-up for an average of 3.0±1.3 years (range 0.5 to
4.8 years). B-cell depletion occurred within 2 weeks in all
patients and persisted for up to 1 year in some. Clinical
activity scores, double-stranded DNA (dsDNA) antibodies,
renal function and proteinuria [urine protein to creatinine
ratio (Upr/cr)] improved in 93% of the patients. Five
patients required multiple courses of RTX for relapse, with
B-cell repopulation. One died of infectious endocarditis
related to severe immunosuppression. In conclusion, our
data support the efficacy of rituximab as adjunctive
treatment for SLE in children. Although rituximab was
well tolerated by the majority of patients, randomized
controlled trials are required to establish its long-term
safety and efficacy.
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Introduction
Systemic lupus erythematosus (SLE) in children is known
to carry a worse prognosis than in adults, especially in
those of African and Hispanic ethnicity [1, 2]. Although
treatment protocols for proliferative lupus nephritis have
evolved during the past two decades, pediatric regimens
have been center based and selectively derived from adult
protocols [3]. These protocols primarily include cyclophos-
phamide (CYC), which carries long-term toxicities related
to malignancy and gonadal dysfunction [4].
Most recently, B-lymphocyte function has been recog-
nized as a major component in the pathogenesis of
autoimmune diseases [5]. Rituximab (RTX), a chimeric
monoclonal antibody directed against CD20 lymphocytes
(commonly called B-cells), was developed as a primary
treatment against B-cell lymphoma [6] and is now approved
for use in the treatment of rheumatoid arthritis [7].
Although clinical trials of the use of RTX in adults with
SLE are substantial and ongoing [8], studies in children
have been limited [9, 10]. A collaborative retrospective and
uncontrolled multicenter experience from Europe reported
mixed results [11]. Unfortunately, that study failed to use a
single protocol, and many patients were treated concurrent-
ly with more toxic medications, which made safety analysis
unreliable [11].
The purpose of our study was to determine the safety
and efficacy of RTX therapy in the treatment of children
with severe SLE. Over the course of 7 years, we
retrospectively assessed the indications and responses to
RTX therapy in a cohort of children with active SLE that
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indications prohibiting the use of more toxic immunosup-
pressant drugs.
Patients and methods
A retrospective analysis was performed on a cohort of 51
patients diagnosed with SLE and lupus nephritis who
received their care at Holtz Children’s Hospital, University
of Miami Miller School of Medicine, between January
1996 and June 2007. The study was approved by the
institutional review board, with waiver of consent authori-
zation, and all subjects were assured anonymity in
compliance with the Health Insurance Portability and
Accountability Act (HIPAA). The medical records were
reviewed for patients’ demographic characteristics, age at
diagnosis, prior and current medical treatments, type of
lupus nephritis and serologic and clinical response to
therapy.
Children were considered eligible for inclusion in the
analysis if they fulfilled the following criteria: (1) American
College of Rheumatology (ACR) criteria for the diagnosis
of SLE [12]; (2) age < 16 years at the time of diagnosis of
SLE; (3) treatment with the anti-CD20 monoclonal anti-
body, rituximab, during the observation period from
January 2000 through October 2007.
Clinical protocol
Rituximab (RTX) was administered weekly for two to four
doses. The initial dose was 188 mg/m
2, infused over 4 h.
Subsequent doses were 375 mg/m
2 per dose, infused over
6 h to 8 h. Premedication initially consisted of diphenhy-
dramine and acetaminophen, administered 30 min before
the rituximab infusion. However, mild infusion reactions,
including pruritis, nausea and emesis, resulted in our adding
hydrocortisone 50–100 mg intravenously 30 min prior to
each infusion. Lymphocyte subsets were assayed before and
after each course of RTX therapy at 1- to 3-month intervals.
This included B cells assayed as CD19+ lymphocytes and
T-cells assayed as CD4 and CD8 lymphocytes as total and
percent of the total lymphocyte cell count. The serum
immunoglobulin levels were measured every 1 to 6 months
prior to and after the course of RTX. Adverse events were
recorded from the time of the first infusion until 1 year
following the treatment course.
Lupus disease activity index and serology
Clinical and biological parameters were assessed prior to
the RTX infusion course, at 1- to 3-month intervals
thereafter. The clinical disease activity was scored with
the SLE-disease activity index 2K (SLEDAI-2K), which
has a maximum activity score of 105 [13]. Laboratory
evaluations included serum complement components (C3
and C4) and anti-double stranded DNA (Anti-dsDNA)
antibody and anti-nuclear antibody (ANA).
Lupus nephritis and renal disease activity
Renal biopsies were classified according to the new
proposed modifications of the World Health Organization
(WHO) classifications [14]. Three patients were treated at
the time they were on hemodialysis for extra-renal
manifestations of SLE. For those patients not on dialysis,
degree of proteinuria and renal function were assessed in
response to RTX therapy. Degree of proteinuria was
determined by the random urine protein to creatinine ratio
(Upr/cr) in milligrams per milligram (mg/mg), with normal
<0.2 and nephrotic range >1.0 [15, 16]. Serum albumin
(Salb) was assayed as an indirect measure of the nephrotic
syndrome. Serum creatinine (Scr) was assayed, and an
estimation of glomerular filtration rate (eGFR) was derived
by the height index formula of Schwartz, expressed as
milliliters per minute per 1.73 meters squared (ml/min per
1.73 m
2)[ 17]. Complete renal remission was defined as
normalization of Upr/cr and eGFR. Partial remission was
defined as > 50% decline in Upr/cr. All serum and urine
chemical analyses and immunoassays were performed in
the central hospital clinical laboratory or the Quest referral
laboratories.
Statistical methods
All data sets were analyzed for Gaussian distribution
using the D’Agostino–Pearson omnibus test for normality.
The data were calculated into average values at baseline
and at 2 months, 4 months, and 6 months after initiation
of treatment. Variables at baseline, during and after the
treatment were compared by the Wilcoxon matched-pairs
signed-ranks test. Differences in parameters between the
2 independent groups were analyzed using Mann-Whit-
ney and the Friedman test with Dunn’s multiple compar-
isons post tests for repeated measures of nonparametric
data. P values of less than 0.05 were considered significant.
All results are expressed as mean ± standard deviation
(SD).
Results
Patients’ demographics
During the period of observation 18 patients were treated
with RTX for at least one course of two to four doses.
414 Pediatr Nephrol (2008) 23:413–419There were 16 female patients and two male patients. Mean
age at the time of diagnosis of SLE was 10.7±2.5 years
(range 7 to 14 years). Mean duration of disease prior to
treatment with RTX was 3.1±2.5 years (range 2 months to
8 years). Age at the time of first RTX treatment was 14.2±
3.3 years, and current age at the time of this report was 17±
5.0 years.
All patients had clinical evidence of lupus nephritis.
Individual patient demographics, clinical manifestations of
SLE and indications for rituximab therapy for patients not
on hemodialysis are shown in Table 1. All patients received
concurrent therapy with low-dose corticosteroids (CSs) and
hydroxychloroquine (HCQ). Sixteen patients had failed or
had suffered toxic effects from multiple courses of
intravenous therapy with cyclophosphamide (CYC) and
corticosteroids. Treatment with RTX included concurrent or
subsequent treatment with maintenance doses of mycophe-
nolate mofetil (MMF) or azathioprine (AZT) similar to
recently published adult protocols [18].
All three patients on hemodialysis responded positively
to the RTX therapy. Patient HD-1 had Raynaud’s syndrome
and finger necrosis; her symptoms resolved, and she
recently received a transplant, 4 years after RTX treatment.
Patient HD-2, who had been on ventilator support with
pneumonitis, pleuritis and carditis for 1 month prior to
receiving RTX, recovered and has been stable on hemodi-
alysis as an outpatient for >4 years since RTX therapy.
Patient HD-3, after 3 years on hemodialysis, developed
debilitating chorea with increased lupus serology. She did
not respond to anti-convulsant therapy. The chorea resolved
within weeks of the RTX therapy. She remains on dialysis
without recurrence of chorea.
Table 1 Patients’ baseline characteristics, indications for rituximab treatment, and clinical course (F female, M male, H Hispanic, B Black, HT
hypertension, CYC cyclophosphamide, CyA cyclosporine A, AZT azathioprine, MMF mycophenolate mofetil, IVIG intravenous therapy with
gamma globulin, CS corticosteroids, HXQ hydroxychloroquine, FR full remission, PR partial remission)
Patient Gender Age at
diagnosis
(years)
Race Indication for rituximab Nephritis
class
Previous and/
or concurrent
therapies
a
Upr/cr (mg/mg) Outcome
Before
RTX
After
RTX
1 F 12.0 B Nephritis, serositis, Coomb’s(+)
anemia, CYC-toxicity
IV CYC, MMF 13.0 0.1 FR
2 M 10.0 W Nephritis, serositis, CS toxicity IV CYC, MMF 2.1 0.6 PR
3 F 11.0 B Nephritis, serositis, Coomb’s(+)
anemia, CYC- toxicity sepsis
IV CYC, MMF 4.0 1.7 PR
4 F 8.0 H Pulmonary HT, nephritis,
Coomb’s(+) anemia
IV-V CYC, MMF, IVIG 2.6 0.2 FR
5 F 12.0 B Ophthalmic vasculitis, nephritis IV-V CYC, AZT 0.4 0.1 FR
6 F 14.0 B Nephritis, Coomb’s(+) anemia,
CS toxicity
NA CYC, AZT, MMF, IVIG 0.6 0.3 PR
7 F 12.0 B Nephritis, serositis,
CYC-toxicity sepsis
IV-V CYC, AZT, MMF, IVIG 2.6 NA Died
8 F 12.0 B Nephritis, serositis,
Coomb’s(+) anemia
IV CYC, AZT, IVIG 3.6 1.9 PR
9 F 14.0 B Nephritis, serositis, ataxia,
miliary tuberculosis
III IVIG 1.7 0.2 FR
10 F 7.0 H Nephritis, serositis, arthritis,
CYC-toxicity sepsis
IV CYC, MMF, IVIG 3.0 0.7 PR
11 F 12.8 H Nephritis, serositis, arthritis,
obesity
V MMF 9.7 0.2 FR
12 F 7.0 B Nephritis, thrombocytopenia,
CYC toxicity
IV-V CYC, AZT, MMF, IVIG,
CyA
5.4 0.2 FR
13 F 7.0 B Nephritis, Coomb’s(+) anemia,
skin vasculitis
IV MMF 1.5 0.2 FR
14 M 12.5 H Nephritis, serositis, arthritis,
CYC-toxicity sepsis
III CYC, MMF, IVIG 2.3 0.8 PR
15 F 13.0 B Nephritis, arthritis,
skin vasculitis, Coomb’s(+)
anemia
IV CYC, MMF, IVIG 6.8 0.9 PR
aAll patients were treated with CS and HXQ
Table 1 Patients’ baseline characteristics, indications for rituximab
treatment, and clinical course (F female, M male, H Hispanic, B Black,
HT hypertension, CYC cyclophosphamide, CyA cyclosporine A, AZT
azathioprine, MMF mycophenolate mofetil, IVIG intravenous therapy
with gamma globulin, CS corticosteroids, HXQ hydroxychloroquine,
FR full remission, PR partial remission)
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Figure 1 shows the average B-cell depletion relative to the
beginning of the first dose of RTX. Patients received an
average of 4.3±1.6 doses overall. B-cell depletion was
achieved within 2 weeks of the first dose of RTX and lasted
an average of 3±4 months (range 3 to 12 months). Five
patients (28%) received repeated courses of RTX therapy
ranging from two to four courses of one to four additional
doses following re-population of the B-cell line in the
setting of clinical relapse of SLE. Overall follow-up period
from the initial dose of RTX to this report was 3.0±
1.3 years. It should be noted that those patients who did not
have clinical relapse were not routinely assayed for
lymphocyte subsets. Therefore, it is not known if or when
those patients with persistent clinical remission had their B-
lymphocyte lineage re-populated.
Table 2 describes the changes in the lymphocyte subsets
from baseline to the nadir drop in the B-lymphocyte
lineage. Total lymphocyte counts, as well as CD4 and
CD8 T-cell counts, tended to be lower before RTX
treatment and increased after RTX therapy. Similarly, the
levels of serum immunoglobulins remained normal in
comparison with the pre-RTX values.
Lupus activity and auto-antibody response
Table 2 and Fig. 2 summarize the clinical response to RTX
therapy. The average lupus activity score (SLEDAI)
improved in all patients. Average dsDNA antibody de-
creased and serum C3 complement increased significantly
after RTX therapy. Other serological parameters showed a
trend towards improvement as well.
All 15 patients not on dialysis had active lupus
nephritis with significant proteinuria. Table 1 provides
detailed information regarding the classification of the
lupus nephritis for each patient, together with extra-renal
manifestations and concurrent or previous therapies, as well
as their final outcome. All parameters improved or
stabilized in 14/15 (93%) patients. Seven had total
remission of proteinuria, while the other seven had partial
remission, with significant improvement in proteinuria and
renal function. Coincident with the improvement in renal
disease, the requirement for maintenance corticosteroid
therapy was reduced in most patients, with an average fall
in corticosteroid dosing from 79±29 mg/m
2 per day before
RTX therapy to 13±20 mg/m
2 per day after RTX therapy
(P<0.0001).
Adverse events
One patient (#7) received three doses of RTX shortly after a
cycle of intravenous cyclophosphamide (CYC) administra-
tion in an effort to control lupus serositis and nephritis. She
developed Staphylococcus aureus endocarditis, with vege-
tations on the mitral and aortic valves. She died after open
heart surgery. This was considered a death from over-
whelming infection most likely related to excessive
immune suppression. Her CD4 count prior to RTX was
220/mm
3, possibly related to prior CYC therapy. At the
time of her death her serum immunoglobulin levels were
normal.
Patient #13 had systemic vasculitis and class IV lupus
nephritis. Since she was only 7 years of age, it was decided
to treat her with intravenous administration of Solu-Medrol
followed by weekly RTX for four doses and concurrent
mycophenolate mofetil (MMF) as induction therapy. She
responded well to RTX, with resolution of her proteinuria
and clinical remission of the lupus nephritis. However, she
Fig. 1 Graph of B-cell depletion over time from before rituximab
therapy to 12–18 months after rituximab therapy. Asterisks indicate
significant difference from the post-rituximab values; P<0.01
Table 2 Clinical parameters before and after rituximab therapy (NS
not significant)
Parameter Before rituximab
therapy
After rituximab
therapy
P
Total lymphocyte count 1044±596 1734±1535 NS
CD4+ lymphocytes 344±217 556±264 NS
CD19+ lymphocytes 243±223 74±71 0.005
Immunoglobulin IgG 1603±848 1596±1055 NS
Immunoglobulin IgM 273±514 283±531 NS
Upr/cr (mg/mg) 4.0±3.5 0.6±0.6 0.001
Serum albumin (g/dl) 2.6±0.7 3.5±0.6 0.001
Scr (mg/dl) 1.2±0.4 0.6±0.2 0.001
eGFR (ml/min/1.73m
2) 86±32 144±37 0.0003
Corticosteroid dose
(mg/m
2 per day)
79±26 13±20 <0.0001
SLEDAI-2K score 47±19 25±14 0.0004
416 Pediatr Nephrol (2008) 23:413–419developed symptoms of cerebral vasculitis, with seizures
and a cerebral infarct, demonstrated by magnetic resonance
imaging (MRI) after her fourth dose of RTX. She was
treated with intravenously administered gamma globulin
(IVIG) and two doses of cyclophosphamide. Her neurologic
deficits resolved and her vasculitis reversed, as demonstrat-
ed by MRI. She remains in remission of the lupus nephritis
and cerebritis 6 months after RTX therapy.
Mild adverse reactions occurred in approximately half
the patients and included pruritis, nausea, or malaise
associated with the infusions. These became less when
hydrocortisone was added to the pre-medication regimen
and the infusion rate was slowed to 6 to 8 hours.
Discussion
To date, this report has provided the largest long-term
experience in children treated with targeted B-cell depletion
using the monoclonal antibody, rituximab, for severe SLE.
We showed a beneficial effect of the drug in over 90% of
the children in this series, which is consistent with that of
previous reports [8, 19–21]. Moreover, we were able to
demonstrate efficacy in controlling proteinuria in conjunc-
tion with a fall in auto-antibodies in those patients with
active lupus nephritis, which mirrored that in a series of
adult patients [19].
B-lymphocyte dysregulation is central in the pathogenesis
of systemic lupus, with disruption of an individual’s immune
homeostasis. These mechanisms are multi-dimensional
and are not limited to the single role of B cells in anti-
body production [22]. Hence, the elimination of the B-cell
lineage, with potential re-population with a “healthier”
line, is theoretically curative to the patient.
The safety of rituximab in young lupus patients remains
unanswered. Most of the patients in our cohort tolerated the
rituximab well. However, as in the European trial [11], our
patients were on variable multi-drug regimens. The one
patient who died did so from infectious complications in
conjunction with severe immune suppression from multiple
cytotoxic agents, including both rituximab and cyclophos-
phamide. Another young patient developed symptoms of
cerebral vasculitis, with seizures and encephalopathy. The
differential diagnosis included the dreaded progressive
multifocal leukoencephalopathy (PML), recently reported
to occur in patients treated with rituximab [23]. Although
she showed clinical recovery after cyclophosphamide
therapy, the case emphasizes the uncharted risks imposed
by the use of drugs without well-studied indications.
The efficacy of rituximab may be short-lived in some
patients. Resistance to RTX B-cell depletion may be related
to antibodies against the human-mouse chimeric protein
[8]. It may also be genetically influenced by polymor-
phisms of the FcRIIIa gene, responsible for the Fc-γ
receptor required for RTX binding to phagocytes [24]. In
our series, all patients had some degree of B-cell depletion
after the initial course of RTX. However, five of the 18
patients (28%) developed clinical relapse in association
with re-population of the B-cell lineage. All but one of
these responded to additional courses of RTX. This is
similar to recent long-term reports in a series of adults [25].
Treatment regimens in children with SLE do not
conform with those of adults developed by carefully
designed randomized controlled trials. This may be
Fig. 2 Composite graphs
depicting response to rituximab
therapy on clinical parameters.
Panel a SLEDAI [13] scores
before and after rituximab ther-
apy. Panel b proteinuria (Upr/cr)
before and after rituximab.
Panel c auto-antibody titers be-
fore and after rituximab. Panel d
serum complements as C3 and
C4 complements. Asterisks in-
dicate significant differences
from the post-rituximab values;
P<0.01
Pediatr Nephrol (2008) 23:413–419 417partially attributable to the fact that children ≤ 16 years of
age are excluded from these trials. This has resulted in an
ambiguous and often anecdotal approach to pediatric
patients, especially those with early onset and severe
disease. Although intravenous cyclophosphamide treat-
ment was established as induction therapy for proliferative
lupus nephritis over two decades ago [26], its short- and
long-term toxicity delayed its incorporation into pediatric
regimens [27]. Paradoxically, those with severe disease
have received excessive courses of toxic medications in
futile efforts to preserve renal function [27]. More recently,
less toxic alternative treatment regimens, including myco-
phenolate mofetil for both induction and maintenance
therapy, have resulted in equal or improved renal survival
over conventional therapies [18, 28]. Since treatment
protocols of children do not conform to conventional
protocols for adults, attempts at reporting multicenter
experiences are hampered by a lack of consistency in
treatment regimens [11, 22]. Therefore, anecdotal center
experiences such as our own are necessary in developing
treatment protocols tailored towards efficacy while decreas-
ing long-term risks on growth, fertility and malignancy.
In conclusion, RTX therapy offers a potential innovation
in the current treatment regimens for children with
aggressive SLE that includes both renal and extra-renal
manifestations. The development of a randomized con-
trolled treatment protocol for induction and maintenance
therapy in pediatric patients is very much warranted.
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